MedDataX Logo

Beta2-mimetic and Central Nervous System

NCT ID: NCT02925130

Last Updated: 2017-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2017-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Beta2-mimetics such as Salbutamol have been shown to have ergogenic effects. Acute and chronic inhaled or oral doses of Salbutamol have been shown to increase whole body exercise and muscle performances. The underlying mechanisms are however unclear. Some data suggest that Salbutamol may have some effects on the central nervous system which may explain the improved exercise and neuromuscular performances. The present study aims to assess the effects of acite inhaled or oral Salbutamol intake on the neuromuscular system by using neurostimulation techniques and magnetic resonance imaging.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The effects of Salbutamol intake will be assessed by using transcranial magnetic stimulation on one hand and magnetic resonance imaging on the other hand. Maximal voluntary activation and cerebral activation will be measured during motor tasks performed until exhaustion after acute inhaled slabutamol intake, acture oral salbutamol intake or oral placebo intake.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adrenergic Beta-2 Agonist Effect Albuterol Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inhaled Salbutamol

Acute inhalation of 800 microgram Salbutamol

Group Type EXPERIMENTAL

Salbutamol

Intervention Type DRUG

Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Oral Salbutamol

Acute oral intake of 4 mg Salbutamol

Group Type EXPERIMENTAL

Salbutamol

Intervention Type DRUG

Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Placebo

Acute oral intake of a placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Acute oral intake of a placebo drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salbutamol

Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.

Intervention Type DRUG

Placebo

Acute oral intake of a placebo drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Albuterol Albuterol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects without respiratory and cordiovascular diseases
* Male
* Age between 18 and 35
* Trained subjects (\>6 hours of physical activity per week)
* Non- or ex-smoker (smoking cessation since at least 1 year)

Exclusion Criteria

* Respiratory, cardiovascular and metabolic diseases
* Neuromuscular diseases
* thyrotoxicosis, or diabetes treated with insulin
* alcoholism
* MRI contraindication
* TMS contraindication
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Grenoble

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michel Guinot, MD PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Grenoble

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Grenoble University Hospital

Grenoble, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

38RC14339

Identifier Type: -

Identifier Source: org_study_id